Other Names for this Disease
Your QuestionHow can I find information on treatment for polyarteritis nodosa? Are there any dietary supplements or other alternative therapies that have been used to treat polyarteritis nodosa?
We have identified the following information that we hope you find helpful. If you still have questions, please contact us.
Questions on this page
- What is polyarteritis nodosa?
- Are there different types of polyarteritis nodosa?
- How might polyarteritis nodosa be treated?
- Are there dietary supplements or other alternative therapies that have been used to treat polyarteritis nodosa?
- Are there clinical trials investigating new therapies for treatment of polyarteritis nodosa?
Few people with polyarteritis nodosa have mild disease that remains stable with nonaggressive therapy; because of the risk for serious health complications, aggressive therapy is often recommended. Treatment may include prednisone in divided doses. Additional therapy, such as cyclophosphamide, chlorambucil, azathioprine, methotrexate, dapsone, cyclosporine, or plasma exchange, may also be recommended. The goal of therapy is remission (to have no active disease) within 6 months or so. At this point the person may be maintained on cyclophosphamide (or other therapy) for a year, before it is tapered and withdrawn over the course of 3 to 6 months.It is very important that people undergoing treatment for polyarteritis nodosa be monitored closely for toxic effects of the drugs or for signs of worsening disease. This monitoring may involve blood counts, urinalyses, serum chemistries, and the ESR on at least monthly intervals.
Vasculitis Clinical Research Consortium (VCRC)
Carol King, MA
715 Albany Street, E-5
Boston, MA 02118
The U.S. National Institutes of Health, through the National Library of Medicine, developed ClinicalTrials.gov to provide patients, family members, and members of the public with current information on clinical research studies. Currently, clinical trials are identified as enrolling individuals with polyarteritis nodosa. After you click on a study, review its "eligibility" criteria to determine its appropriateness. Use the study’s contact information to learn more. Check this site often for regular updates.
You can also contact the Patient Recruitment and Public Liaison (PRPL) Office at the National Institutes of Health (NIH). We recommend calling the toll-free number 1-800-411-1222 to speak with a specialist, who can help you determine if you are eligible for any clinical trials.
If you are interested in enrolling in a clinical trial, you can find helpful general information on clinical trials at the following ClinicalTrials.gov Web page.
Resources on many charitable or special-fare flights to research and treatment sites and low-cost hospitality accommodations for outpatients and family members, as well as ambulance services, are listed on the Web site of the Office of Rare Diseases Research (ORDR), part of the National Institutes of Health.
- Sergent JS. Polyarteritis and Related Disorders. In: Firestein. Kelley’s Textbook of Rheumatology, 8th ed. Philadelphia PA: WB Saunders Company; 2008;
- Polyarteritis nodosa. MedlinePlus. 2010; http://www.nlm.nih.gov/medlineplus/ency/article/001438.htm. Accessed 1/16/2012.
- Nakamura T, Kanazawa N, Ikeda T, Yamamoto Y, Nakabayashi K, Ozaki S, Furukawa F. Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria. Arch Dermatol Res. 2009; 301:117-121.